Premium
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study
Author(s) -
Pierno S,
Didonna M P,
Cippone V,
Luca A,
Pisoni M,
Frigeri A,
Nicchia G P,
Svelto M,
Chiesa G,
Sirtori C,
Scanziani E,
Rizzo C,
Vito D,
Conte Camerino D
Publication year - 2006
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0706917
Subject(s) - fluvastatin , atorvastatin , fenofibrate , skeletal muscle , medicine , endocrinology , sarcolemma , pharmacology , chemistry , simvastatin
Background and purpose: Skeletal muscle injury by hypolipidemic drugs is not fully understood. An extensive analysis of the effect of chronic treatment with fluvastatin (5 mgkg ‐1 and 20 mgkg ‐1 ), atorvastatin (10 mgkg ‐1 ) and fenofibrate (60 mgkg ‐1 ) on rat skeletal muscle was undertaken. Experimental approach: Myoglobinemia as sign of muscle damage was measured by enzymatic assay. Histological and immunohistochemical techniques were used to estimate muscle integrity and the presence of aquaporin‐4, a protein controlling water homeostasis. Electrophysiological evaluation of muscle Cl ‐ conductance (gCl) and mechanical threshold (MT) for contraction, index of intracellular calcium homeostasis, was performed by the two‐intracellular microelectrodes technique. Key results: Fluvastatin (20 mgkg ‐1 ) increased myoglobinemia. The lower dose of fluvastatin did not modify myoglobinemia, but reduced urinary electrolytes, suggesting direct effects on renal function. Atorvastatin also increased myoglobinemia, with slight effects on urinary parameters. No treatment caused any histological damage to muscle or modification in the number of fibres expressing aquaporin‐4. Either fluvastatin (at both doses) or atorvastatin reduced sarcolemma gCl and changed MT. Both statins produced slight effects on total cholesterol, suggesting that the observed modifications occur independently of HMGCoA‐reductase inhibition. Fenofibrate increased myoglobinemia and decreased muscle gCl, whereas it did not change the MT, suggesting a different mechanism of action from the statins. Conclusions and Implications This study identifies muscle gCl and MT as early targets of drugs action that may contribute to milder symptoms of myotoxicity, such as muscle cramps, while the increase of myoglobinemia is a later phenomenon. British Journal of Pharmacology (2006) 149 , 909–919. doi: 10.1038/sj.bjp.0706917